Thank you again, eagle8. Since this may be helpful context for understanding what NWBO now controls, or is positioned to deploy, here is a brief breakdown of how IRIS works, why it matters scientifically, and how it connects with the broader immune programming framework behind DCVax. Everything here is grounded in public records and peer-reviewed literature, with traceable sources throughout.
IRIS is not a drug. It is an AI signal detector built for the immune system.
It does not attack. It listens. It reads the transcriptional chaos of a tumor’s RNA and uses artificial intelligence to reconstruct where the instructions went wrong, where splicing took a different path. Where a junction skipped. Where a cryptic exon formed. Where the body failed to clean the code. It identifies those errors with machine learning, but ranks them with immunologic logic. IRIS does not just find anomalies. It prioritizes terrain.
It does this in five steps:
1. IRIS uses deep AI modeling to scan tumor transcriptomes and identify splice variants that are statistically absent in normal tissues.
2. It maps these isoforms onto predicted peptide fragments that may be presented on MHC class I and II molecules.
3. It filters that list using proprietary algorithms trained on mass spectrometry datasets to flag only fragments that are immunologically visible.
4. It selects these peptides for synthetic manufacture.
5. It prepares them for dendritic cell pulsing.
At that point, Flaskworks and Eden take over. IRIS generates the terrain. Eden matches it to patient-specific immune history and calibrates it using booster class logic. These are not passive enhancers. They are immunologic codices. Each class, danger signals, viral primers, checkpoint sensitizers, cytokine inductors, and memory extenders, engages a different layer of the system. The result is not just antigen recognition, but sustained immunity. A memory structure forms across MHC pathways and innate reactivity, reinforced with layered ignition. This is what makes the system programmable. This is how DCVax becomes an immune rehearsal loop, not a one-shot therapy. And it begins with the terrain that IRIS sees.
The platform was invented by Dr. Yi Xing, Dr. Robert Prins, and Dr. Linda Liau. The corresponding patent (EP4504750A1) was filed in 2022 and published in 2024. It is co-owned by The Regents of the University of California and Children’s Hospital of Philadelphia (CHOP). That matters.
CHOP’s participation signals the platform’s intent: pediatric cancers.
IRIS was designed for tumors that mutate silently, where DNA analysis fails to produce usable immune targets. That includes DIPG, ATRT, and pediatric gliomas with low tumor mutational burden. CHOP’s involvement points directly at these childhood cancers, and the IRIS method bypasses the need for radiation, chemotherapy, or surgery. All it requires is blood draw, AI terrain mapping, dendritic pulsing, and immune response.
Because of this design, IRIS is likely suitable for use in multiple pediatric tumor types (just to name a few):
• Diffuse Intrinsic Pontine Glioma (DIPG): The original target. IRIS can detect splicing-derived junctions from H3 mutations or enhancer hijacking.
• Atypical Teratoid Rhabdoid Tumor (ATRT): Splice variants from epigenetic dysregulation provide potential terrain.
• Ependymoma (RELA-fusion): RNA splicing errors around the fusion junction become visible terrain.
• Infantile Fibrosarcoma (ETV6-NTRK3): Aberrant transcription after fusion creates splicing-derived peptides.
• Pediatric Leptomeningeal Glioneuronal Tumor: Deep splicing fragments not seen in normal CNS tissue can be targeted without systemic damage.
• Pediatric Clear Cell Sarcoma of the Kidney: Rearrangement-driven transcript errors expose immune targets invisible to whole-exome sequencing.
And now that Dr. Liau is Chief Scientific Officer of NWBO, the method she helped patent is one she may also help operationalize. That would mean seamless integration of IRIS terrain logic with NWBO’s Eden compiler, Flaskworks hardware, and cryogenic immune infrastructure.
It also means that NWBO, already validated for survival with DCVax-L, could inherit a pediatric terrain stack that is AI-optimized, fully patented, and already in trial at CHOP.
IRIS identifies the terrain.
Artificial intelligence ranks it.
Flaskworks enables manufacturing.
Eden assigns immune calibration.
Each function is distinct.
But the system is already in place.
Bullish
Market Data 
Markets 
AI
